Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Although Moderna Inc. doesn’t yet have any marketed products, analysts are encouraged that the Cambridge, MA, firm that was first into the clinic with a vaccine for the novel coronavirus SARS-CoV-2 can succeed in developing a COVID-19 vaccine based on findings from its development of vaccines for other infectious diseases.

The company will be providing more details on its vaccines program overall, including the mRNA-1273 coronavirus vaccine, at a 14 April investor day, but SVB Leerink analyst Geoffrey Porges put out a